XRCC6 Antibody

What is XRCC6 and why is it important in research?

XRCC6 encodes the Ku70 protein, a critical component of the DNA-dependent protein kinase complex (DNA-PK). Ku70 forms a heterodimer with Ku80 that binds to DNA ends and functions as a single-stranded DNA-dependent ATP-dependent helicase. This complex plays essential roles in:

• Non-homologous end joining (NHEJ) DNA repair

• Double-strand break repair

• V(D)J recombination

• DNA replication

The significance of XRCC6 extends to cancer research, as it has been found overexpressed in several tumor types including osteosarcoma, head and neck squamous cell carcinoma, and lung cancer . This overexpression correlates with clinical parameters such as tumor stage and size, making XRCC6 antibodies valuable tools for investigating cancer biology and potential therapeutic targets.

What are the key applications for XRCC6 antibodies in research?

XRCC6 antibodies can be utilized in multiple experimental approaches:

These applications have been validated across multiple human cell lines including HeLa, HepG2, Jurkat, K-562, and multiple cancer tissue samples .

How should researchers select the appropriate XRCC6 antibody for their specific application?

When selecting an XRCC6 antibody, consider these critical factors:

• Target species compatibility: Ensure the antibody has been validated for your species of interest. Many XRCC6 antibodies show reactivity with human, mouse, and rat samples .

• Application validation: Verify that the antibody has been tested in your specific application. For instance, antibody 66607-1-Ig has been validated for WB, IHC, IF/ICC, IF-P, and FC, while others may have more limited application profiles .

• Clonality considerations:

  • Monoclonal antibodies (e.g., 66607-1-Ig) provide high specificity and reproducibility

  • Polyclonal antibodies (e.g., 10723-1-AP) often offer higher sensitivity and multiple epitope recognition

• Immunogen information: For targeted studies, select antibodies raised against specific regions of interest in the XRCC6 protein. For example, antibody A97102 targets amino acids 554-603 of human XRCC6 .

• Publication record: Antibodies with documented use in peer-reviewed research demonstrate reliability. For instance, antibody 10723-1-AP has been cited in 34 publications for Western blot applications .

Cell Lysate Preparation for Western Blot:

• Harvest cells during exponential growth phase for optimal XRCC6 detection

• Lyse cells in RIPA buffer supplemented with protease inhibitors

• Sonicate briefly to shear DNA and reduce sample viscosity

• Centrifuge at 14,000×g for 15 minutes at 4°C to remove debris

• Quantify protein concentration using Bradford or BCA assay

• Load 20-40 μg of total protein per lane for reliable XRCC6 detection

Tissue Preparation for Immunohistochemistry:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin following standard protocols

• Section tissues at 4-6 μm thickness

• For XRCC6 antigen retrieval, use TE buffer pH 9.0 (preferred) or citrate buffer pH 6.0

• Block endogenous peroxidase activity with 3% hydrogen peroxide

• Use appropriate blocking solution to minimize background staining

Successful XRCC6 immunohistochemistry has been demonstrated in human breast, colon, and lung cancer tissues .

Why might researchers observe variable molecular weights for XRCC6 in Western blot experiments?

XRCC6/Ku70 has a calculated molecular weight of 75 kDa but is typically observed at approximately 70 kDa on Western blots . This discrepancy may be attributed to:

• Post-translational modifications: XRCC6 undergoes multiple modifications including phosphorylation and acetylation that can alter migration patterns

• Sample preparation conditions: Denaturing conditions can affect protein conformation and migration

• Gel concentration effects: The percentage of acrylamide in gels can influence apparent molecular weight

• Splice variants: Although less common for XRCC6, potential splice variants may display different molecular weights

For verification of specificity, researchers can perform blocking experiments with the immunizing peptide as demonstrated with antibody A97102, where the signal was eliminated when the antibody was pre-incubated with the immunogen .

How can researchers optimize detection of XRCC6 in challenging samples or low-expression scenarios?

For samples with low XRCC6 expression or challenging detection:

• Enrichment strategies:

  • Perform subcellular fractionation to isolate nuclear fractions where XRCC6 predominantly localizes

  • Use immunoprecipitation to concentrate XRCC6 before Western blot analysis

• Signal amplification approaches:

  • For IHC/IF: Implement tyramide signal amplification (TSA) systems

  • For Western blot: Use high-sensitivity ECL substrates or fluorescent secondary antibodies

• Protocol optimization:

  • Extend primary antibody incubation time (overnight at 4°C)

  • Adjust blocking conditions to reduce background while preserving specific signal

  • Optimize antigen retrieval methods for fixed tissues

• Alternative detection methods:

  • When Western blot yields inconsistent results, consider alternative approaches like ELISA or flow cytometry

Empirical testing using positive control samples, such as LNCaP, HeLa, or K-562 cells which express detectable levels of XRCC6, should be performed to establish optimal conditions .

How can XRCC6 antibodies be utilized to investigate DNA damage and repair mechanisms?

XRCC6 antibodies can provide valuable insights into DNA damage response through sophisticated experimental approaches:

• Laser microirradiation combined with immunofluorescence:

  • Track XRCC6 recruitment to DNA damage sites in real-time

  • Quantify accumulation kinetics at double-strand breaks

  • Assess co-localization with other DNA repair factors

• Chromatin immunoprecipitation (ChIP) assays:

  • Map XRCC6 binding to specific genomic regions after DNA damage

  • Identify sequence preferences for XRCC6 binding to damaged DNA

  • Analyze temporal dynamics of recruitment and release

• Proximity ligation assays (PLA):

  • Visualize and quantify interactions between XRCC6 and other repair proteins in situ

  • Detect conformational changes in the Ku70/80 complex upon DNA binding

• CRISPR-Cas9 genome editing combined with immunodetection:

  • Generate XRCC6 mutants and assess effects on localization and function

  • Create domain-specific modifications to dissect structure-function relationships

These approaches have advanced our understanding of how XRCC6/Ku70 contributes to genome stability and cellular responses to genotoxic stress .

What is the significance of XRCC6 in cancer research and how can antibodies facilitate these investigations?

XRCC6 has emerged as a significant factor in cancer biology, with antibody-based detection methods revealing important insights:

• Expression profiling across cancer types:

  • Immunohistochemistry studies show XRCC6 overexpression in osteosarcoma, correlating with clinical stage and tumor size

  • Western blot analysis demonstrates elevated XRCC6 levels in multiple cancer cell lines

• Functional investigations:

  • siRNA knockdown experiments reveal that XRCC6 inhibition impairs cancer cell proliferation through G2/M phase arrest

  • Colony formation assays show reduced colony numbers and sizes following XRCC6 knockdown in osteosarcoma cells

• Mechanistic studies:

  • Co-immunoprecipitation with XRCC6 antibodies can identify novel protein interactions in cancer cells

  • ChIP experiments can map altered binding patterns of XRCC6 at regulatory genomic regions in tumors

• Potential therapeutic applications:

  • XRCC6 antibodies can help evaluate the efficacy of DNA repair inhibitors

  • Monitor changes in XRCC6 expression or localization during treatment response

Research has demonstrated that high XRCC6 expression contributes to cell proliferation and carcinogenesis in multiple cancer types, including gastric cancer and hepatocellular carcinoma, suggesting its potential as both a biomarker and therapeutic target .

How can researchers investigate post-translational modifications of XRCC6 using specialized antibodies?

Post-translational modifications (PTMs) of XRCC6/Ku70 regulate its activity, localization, and interactions. Specialized antibodies recognizing specific modifications provide valuable research tools:

• Acetylation-specific antibodies:

  • Antibodies targeting acetylated lysine residues (e.g., acLys542) detect regulation of XRCC6 function

  • Applications include monitoring acetylation status during DNA damage response

  • Can be used to assess effects of histone deacetylase inhibitors on XRCC6 regulation

• Phosphorylation-specific antibodies:

  • Detect DNA damage-induced phosphorylation events

  • Monitor cell cycle-dependent modifications of XRCC6

  • Study signaling pathways regulating XRCC6 activity

• Experimental approaches using modification-specific antibodies:

  • Immunoprecipitation with PTM-specific antibodies followed by mass spectrometry

  • ChIP-seq using modification-specific antibodies to map genome-wide binding patterns

  • Proximity ligation assays to detect modification-dependent protein interactions

• Verification strategies:

  • Use phosphatase or deacetylase treatments as negative controls

  • Employ CRISPR-edited cell lines with mutation of specific modification sites

  • Implement both PTM-specific and total XRCC6 antibodies in parallel experiments

These approaches have revealed that PTMs critically regulate XRCC6's functions in DNA repair, transcriptional regulation, and protein-protein interactions in both normal and pathological contexts.

What emerging techniques might enhance XRCC6 antibody applications in molecular and cellular research?

Several cutting-edge methodologies are poised to expand the utility of XRCC6 antibodies:

• Spatial proteomics approaches:

  • Imaging mass cytometry combined with XRCC6 antibodies for single-cell spatial analysis

  • Proximity-dependent biotinylation (BioID or TurboID) with XRCC6 fusion proteins to map local interactomes

• Live-cell antibody applications:

  • Cell-permeable nanobodies or intrabodies against XRCC6 for dynamic imaging

  • Optogenetic control of XRCC6 function using antibody-based tethering systems

• Single-molecule techniques:

  • Super-resolution microscopy with XRCC6 antibodies to visualize DNA repair complexes beyond the diffraction limit

  • Single-molecule pull-down assays to analyze stoichiometry and composition of XRCC6-containing complexes

• Computational integration:

  • Machine learning algorithms to analyze immunostaining patterns across cancer samples

  • Systems biology approaches incorporating antibody-derived data into network models of DNA repair

These emerging technologies will enable researchers to address fundamental questions about XRCC6's role in maintaining genome integrity with unprecedented resolution and precision.